Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) Consolidated Net Income: 2019-2025

Historic Consolidated Net Income for Benitec Biopharma (BNTC) over the last 5 years, with Jun 2025 value amounting to -$8.8 million.

  • Benitec Biopharma's Consolidated Net Income fell 90.10% to -$8.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$38.5 million, marking a year-over-year decrease of 78.26%. This contributed to the annual value of -$38.5 million for FY2025, which is 78.26% down from last year.
  • Latest data reveals that Benitec Biopharma reported Consolidated Net Income of -$8.8 million as of Q2 2025, which was up 39.37% from -$14.5 million recorded in Q1 2025.
  • Over the past 5 years, Benitec Biopharma's Consolidated Net Income peaked at -$3.5 million during Q1 2022, and registered a low of -$14.5 million during Q1 2025.
  • Over the past 3 years, Benitec Biopharma's median Consolidated Net Income value was -$5.5 million (recorded in 2023), while the average stood at -$6.9 million.
  • Per our database at Business Quant, Benitec Biopharma's Consolidated Net Income grew by 11.79% in 2024 and then plummeted by 250.11% in 2025.
  • Benitec Biopharma's Consolidated Net Income (Quarterly) stood at -$4.8 million in 2021, then declined by 15.95% to -$5.6 million in 2022, then decreased by 23.38% to -$6.9 million in 2023, then slumped by 43.98% to -$10.0 million in 2024, then crashed by 90.10% to -$8.8 million in 2025.
  • Its last three reported values are -$8.8 million in Q2 2025, -$14.5 million for Q1 2025, and -$10.0 million during Q4 2024.